Go to content

Myasthenia Gravis (MG) resource utilization, epidemiology, survival and treatment patterns (MG-REST): estimating the clinical and economic burden in Ontario, Canada

Client: IQVIA Solutions Canada Inc.

Project ID: P2022-128/ 2024 0970 343 000

Research Question/Objectives: The epidemiology MG has been previously studied using ICES admin data using a previously-validated algorithm developed with ICES data holdings, but incidence and prevalence estimates are now outdated. Additionally, estimates for survival, mortality rate, healthcare costs, and healthcare resource utilization (HCRU) of MG patients in Canada have not been published.

Using a MG adult population identified with a validated algorithm, this descriptive study will focus on the following objectives from 2013-2019:

1. Primary objectives (1) HCRU + healthcare costs by MG phase (2) overall survival and mortality rate (3) Treatment patterns, and (4) Incidence + prevalence; and
2. Secondary objectives (5) Demographic + clinical characteristics (6) MG exacerbations and myasthenic crisis events

Availability Of Results: In progress